• Unlike any other treatment, Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved* disease-modifying osteoarthritis drug (DMOAD) in the veterinary market.
  
• It slows the disease cycle of non-infectious arthritis in dogs and supports the cartilage matrix repair process, while diminishing joint damage.
  
• Treats the underlying causes of canine arthritis, rather than just the symptoms.
  
• Is proven to slow the disease cycle, support tissue repair, diminish joint and joint fluid damage.
  
• Adequan® Canine is an intramuscular injection that reaches the joint within two hours. It delivers the dose more rapidly to the joints with an intramuscular injection than is possible with an oral medication.
  
• After entering the cartilage, Adequan® Canine lasts for 72 hours.
  
• Adequan® Canine contains a mixture of polysulfated GAGs (glycosaminaglycans) that helps it bind with connective tissue.
  
• This intramuscular injection allows delivery of high levels of GAGs to synovial joints by avoiding the digestive enzymes of the GI tract.
  
• Its relatively low molecular weight (3,000 to 15,000 daltons) allows PSGAG to move from the bloodstream through the synovial membrane and into the synovial fluid.
  
• This intramuscular injection helps keep joints lubricated, making movement easier and increases comfort by indirectly reducing inflammation.
  
• Adequan® Canine is a prescription-only product that can be dispensed and administered only by licensed veterinarians.

*NADA #141-038, Approved by FDA